[go: up one dir, main page]

UA110612C2 - Похідні 1-аміно-2-циклопропілетилборонової кислоти - Google Patents

Похідні 1-аміно-2-циклопропілетилборонової кислоти

Info

Publication number
UA110612C2
UA110612C2 UAA201212379A UAA201212379A UA110612C2 UA 110612 C2 UA110612 C2 UA 110612C2 UA A201212379 A UAA201212379 A UA A201212379A UA A201212379 A UAA201212379 A UA A201212379A UA 110612 C2 UA110612 C2 UA 110612C2
Authority
UA
Ukraine
Prior art keywords
cyclopropylethyrboronic
derivatives
amino
acid
present
Prior art date
Application number
UAA201212379A
Other languages
English (en)
Russian (ru)
Inventor
Пол Е. Флемінг
Цзин Лі
Original Assignee
Мілленніум Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110612(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мілленніум Фармасьютікалз, Інк. filed Critical Мілленніум Фармасьютікалз, Інк.
Publication of UA110612C2 publication Critical patent/UA110612C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

У даному винаході представлені нові сполуки, корисні як інгібітори протеасоми. У даному винаході представлені також фармацевтичні композиції, що містять сполуки даного винаходу, і застосування цих композицій при лікуванні різних захворювань.
UAA201212379A 2010-03-31 2011-03-30 Похідні 1-аміно-2-циклопропілетилборонової кислоти UA110612C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31
PCT/US2011/030455 WO2011123502A1 (en) 2010-03-31 2011-03-30 Derivatives of 1-amino-2-cyclopropylethylboronic acid

Publications (1)

Publication Number Publication Date
UA110612C2 true UA110612C2 (uk) 2016-01-25

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201212379A UA110612C2 (uk) 2010-03-31 2011-03-30 Похідні 1-аміно-2-циклопропілетилборонової кислоти

Country Status (26)

Country Link
US (3) US8513218B2 (uk)
EP (1) EP2552216B1 (uk)
JP (1) JP5933523B2 (uk)
KR (1) KR20130036228A (uk)
CN (3) CN107266485A (uk)
AR (1) AR080863A1 (uk)
AU (1) AU2011235227B2 (uk)
CA (1) CA2794334C (uk)
CL (1) CL2012002733A1 (uk)
CO (1) CO6630162A2 (uk)
CR (1) CR20120529A (uk)
DO (1) DOP2012000257A (uk)
EA (1) EA029521B1 (uk)
EC (1) ECSP12012249A (uk)
MA (1) MA34169B1 (uk)
MX (1) MX2012011298A (uk)
NZ (1) NZ602622A (uk)
PE (1) PE20130383A1 (uk)
PH (1) PH12012501943A1 (uk)
RU (1) RU2012146101A (uk)
SG (1) SG184222A1 (uk)
TN (1) TN2012000465A1 (uk)
UA (1) UA110612C2 (uk)
UY (1) UY33314A (uk)
WO (1) WO2011123502A1 (uk)
ZA (2) ZA201207406B (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629084C (en) 2005-11-09 2015-08-11 Proteolix, Inc. Compounds for inhibition of chymotrypsin-like activity of the 20s proteasome
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
FI2318419T4 (fi) 2008-06-17 2025-01-29 Takeda Pharmaceuticals Co Boronaattiesteriyhdisteitä ja niiden farmaseuttisia koostumuksia
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
KR20110073584A (ko) 2008-10-21 2011-06-29 오닉스 세라퓨틱스, 인크. 펩티드 에폭시케톤과의 병용 요법
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
SMT202000248T1 (it) 2010-08-10 2020-07-08 Rempex Pharmaceuticals Inc Derivati di estere di acido boronico ciclico e relativi usi terapeutici
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
SG10201605152SA (en) * 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008628A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
JP2016531886A (ja) 2013-10-03 2016-10-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法
USRE49816E1 (en) 2014-01-10 2024-01-30 Cornell University Dipeptides as inhibitors of human immunoproteasomes
PL3140310T3 (pl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Synteza soli boronianowych i ich zastosowanie
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EA201691988A1 (ru) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
JP2017524652A (ja) 2014-05-20 2017-08-31 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
MX2016016666A (es) 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
CN114796207A (zh) 2014-08-18 2022-07-29 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US11066397B2 (en) 2015-10-15 2021-07-20 Cornell University Proteasome inhibitors and uses thereof
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
JP2001511814A (ja) 1997-02-15 2001-08-14 プロスクリプト・インコーポレイテッド ＮＦ−κＢの阻害を介する梗塞の治療
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
US20010012854A1 (en) 1997-12-16 2001-08-09 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
PL201411B1 (pl) 2000-02-29 2009-04-30 Bristol Myers Squibb Co Zastosowanie entekawiru do wytwarzania kompozycji farmaceutycznej
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
DK1355910T3 (da) 2001-01-25 2011-06-27 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulering af borsyreforbindelser
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003059898A2 (en) 2002-01-08 2003-07-24 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PE20050360A1 (es) * 2003-08-14 2005-06-10 Cephalon Inc Inhibidores del proteasoma
SG182999A1 (en) 2004-03-30 2012-08-30 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20150010802A (ko) 2007-08-06 2015-01-28 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
FI2318419T4 (fi) 2008-06-17 2025-01-29 Takeda Pharmaceuticals Co Boronaattiesteriyhdisteitä ja niiden farmaseuttisia koostumuksia
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты

Also Published As

Publication number Publication date
EA201290980A1 (ru) 2013-03-29
ZA201308086B (en) 2015-03-25
CR20120529A (es) 2013-01-11
CA2794334C (en) 2018-06-12
MX2012011298A (es) 2012-11-06
US20140011998A1 (en) 2014-01-09
SG184222A1 (en) 2012-10-30
JP2013523760A (ja) 2013-06-17
US20140179631A1 (en) 2014-06-26
ZA201207406B (en) 2014-01-29
EP2552216B1 (en) 2018-01-24
AU2011235227A1 (en) 2012-10-18
KR20130036228A (ko) 2013-04-11
CN102892291A (zh) 2013-01-23
EA029521B1 (ru) 2018-04-30
US8703743B2 (en) 2014-04-22
NZ602622A (en) 2015-01-30
EP2552216A1 (en) 2013-02-06
MA34169B1 (fr) 2013-04-03
JP5933523B2 (ja) 2016-06-08
CO6630162A2 (es) 2013-03-01
CL2012002733A1 (es) 2013-01-25
ECSP12012249A (es) 2012-11-30
PH12012501943A1 (en) 2017-08-23
US20110245203A1 (en) 2011-10-06
US9023832B2 (en) 2015-05-05
AR080863A1 (es) 2012-05-16
CN106008570A (zh) 2016-10-12
AU2011235227B2 (en) 2016-09-08
CN107266485A (zh) 2017-10-20
UY33314A (es) 2011-10-31
US8513218B2 (en) 2013-08-20
CA2794334A1 (en) 2011-10-06
TN2012000465A1 (en) 2014-01-30
EP2552216A4 (en) 2013-07-31
RU2012146101A (ru) 2014-05-10
WO2011123502A1 (en) 2011-10-06
DOP2012000257A (es) 2012-11-15
PE20130383A1 (es) 2013-04-24

Similar Documents

Publication Publication Date Title
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201070247A1 (ru) Ингибиторы протеасом
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201500432A1 (ru) Соединения боронатного эфира и его фармацевтические составы
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201490688A1 (ru) 2-тиопиримидиноны
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201591180A1 (ru) Составы ингибитора lfa-1
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний